

胰腺癌是恶性程度最高的实体肿瘤之一,超过90%为胰腺导管腺癌。2025年我国新发病例约13.4万,死亡约11.8万,发病率仍以每年2.3%的速度上升;局部晚期及转移性患者占比超过60%,是临床治疗的绝对主体。其核心困境在于早期症状非特异,多数患者确诊时已丧失根治性手术机会,总体5年生存率长期徘徊在13%左右,是主要癌症中唯一低于20%的瘤种。根治性切除仍是唯一治愈手段,但仅10%—15%的患者具备条件,术后5年生存率可达43%;而存在远处转移者则骤降至不足4%。近年来治疗格局正在发生实质性变化:KRAS G12D抑制剂联合PD-L1阻断在经治转移性患者中取得43.2%的客观缓解率和81.1%的疾病控制率,且为无化疗方案;针对KRAS野生型患者的NRG1融合、BRAF改变等少见靶点也逐步进入临床视野。局部晚期患者通过靶向、免疫与化疗的联合转化治疗,部分可获得重新手术的机会。早期发现仍是改善预后的根本杠杆,新发糖尿病已被确认为最重要的非遗传风险信号之一。
Pancreatic cancer is among the most lethal solid malignancies; over 90% are pancreatic ductal adenocarcinoma (PDAC). It is the third leading cause of cancer death in the United States, with an estimated 67,530 new cases and 52,740 deaths in 2026. The overall five-year relative survival rate remains stalled at 13%, the only major cancer below 20%. The central obstacle is late presentation: early symptoms are nonspecific, and most patients have locally advanced or metastatic disease at diagnosis. Curative surgery is feasible in only 10%–15%, yet those patients achieve five-year survival up to 43%, falling below 4% with distant metastasis. The therapeutic landscape is nonetheless shifting. KRAS, mutated in over 90% of PDAC, has moved from an “undruggable” target to a clinical reality: a selective KRAS G12D inhibitor combined with PD-L1 blockade produced a 43.2% objective response rate and 81.1% disease control rate in pretreated metastatic patients, without chemotherapy. Actionable alterations in KRAS wild-type tumors—including NRG1 fusions and BRAF changes—are also entering practice. Early detection remains the definitive lever, with new-onset diabetes now recognized as the most significant non-genetic risk factor.